+

WO1999035266A3 - Urotensine humaine ii - Google Patents

Urotensine humaine ii Download PDF

Info

Publication number
WO1999035266A3
WO1999035266A3 PCT/US1999/000489 US9900489W WO9935266A3 WO 1999035266 A3 WO1999035266 A3 WO 1999035266A3 US 9900489 W US9900489 W US 9900489W WO 9935266 A3 WO9935266 A3 WO 9935266A3
Authority
WO
WIPO (PCT)
Prior art keywords
human urotensin
polypeptides
polynucleotides
disclosed
methods
Prior art date
Application number
PCT/US1999/000489
Other languages
English (en)
Other versions
WO1999035266A2 (fr
Inventor
Jeffrey S Culp
Dean E Mcnulty
Catherine E Ellis
Stephen A Douglas
Robert N Willette
Nambi V Aiyar
Anne Romanic Arnold
Nassirah Khandoudi
Bernard Gout
Kamal Al-Barazanji
Original Assignee
Smithkline Beecham Corp
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/027,381 external-priority patent/US6075137A/en
Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Corp
Priority to JP2000527650A priority Critical patent/JP2002500045A/ja
Priority to EP99902140A priority patent/EP1045908A2/fr
Publication of WO1999035266A2 publication Critical patent/WO1999035266A2/fr
Publication of WO1999035266A3 publication Critical patent/WO1999035266A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)

Abstract

L'invention concerne des polypeptides et des polynucléotides d'urotensine humaine II, ainsi que des procédés de production de ces polypeptides par des techniques de recombinaison. L'invention concerne également des procédés d'utilisation thérapeutique et des méthodes diagnostiques de ces polypeptides et polynucléotides d'urotensine humaine II.
PCT/US1999/000489 1998-01-09 1999-01-08 Urotensine humaine ii WO1999035266A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000527650A JP2002500045A (ja) 1998-01-09 1999-01-08 ヒトウロテンシンｉｉ
EP99902140A EP1045908A2 (fr) 1998-01-09 1999-01-08 Urotensine humaine ii

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US7238398P 1998-01-09 1998-01-09
US7361698P 1998-02-04 1998-02-04
US09/027,381 US6075137A (en) 1998-01-09 1998-02-20 Human urotensin II
US22574799A 1999-01-05 1999-01-05
US09/225,747 1999-01-05
US60/073,616 1999-01-05
US09/027,381 1999-01-05
US60/072,383 1999-01-05

Publications (2)

Publication Number Publication Date
WO1999035266A2 WO1999035266A2 (fr) 1999-07-15
WO1999035266A3 true WO1999035266A3 (fr) 1999-09-30

Family

ID=27487580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000489 WO1999035266A2 (fr) 1998-01-09 1999-01-08 Urotensine humaine ii

Country Status (3)

Country Link
EP (1) EP1045908A2 (fr)
JP (1) JP2002500045A (fr)
WO (1) WO1999035266A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786489B1 (fr) * 1998-11-26 2002-12-27 Inst Nat Sante Rech Med Urotensines ii de mammiferes et leurs appications
EP1136503A1 (fr) * 1998-11-30 2001-09-26 Takeda Chemical Industries, Ltd. Nouvelle substance physiologiquement active et ses procedes d'obtention et d'utilisation
AU6514400A (en) * 1999-08-24 2001-03-19 Regents Of The University Of California, The Method of identifying urotensin ii receptor antagonists
WO2002014513A1 (fr) * 2000-08-10 2002-02-21 Takeda Chemical Industries, Ltd. Utilisation de polypeptide
WO2002015934A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents prophylactiques et remedes contre des maladies du systeme nerveux central
EP1241479B1 (fr) * 2001-03-12 2007-08-01 Immundiagnostik AG Méthode pour la détermination d'urotensine II dans les fluides corporels et diagnostic des maladies cardiovasculaires
GB0216191D0 (en) * 2002-07-11 2002-08-21 Univ Leicester Plasma urotensin in human heart failure
US20060183174A1 (en) * 2005-02-11 2006-08-17 Leong Ng Diagnosis
WO2009033823A1 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'une combinaison de peptide comprenant urotensine ii en tant qu'agent thérapeutique
FR2982488B1 (fr) * 2011-11-10 2013-12-27 Univ Rouen Urotensine ii pour son utilisation dans le traitement et/ou la prevention de pathologies impliquant la motilite gastrique

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049386A1 (fr) * 1996-06-26 1997-12-31 Peptide Delivery Systems Pty. Ltd. Administration de peptides par voie orale

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049386A1 (fr) * 1996-06-26 1997-12-31 Peptide Delivery Systems Pty. Ltd. Administration de peptides par voie orale

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CONLON J.M. ET AL.: "Distribution and molecular forms of Urotensin II and its role in cardiovascular regulation in vertebrates", THE JOURNAL OF EXPERIMENTAL ZOOLOGY, vol. 275, no. 2 3, 1 June 1996 (1996-06-01) - 15 June 1996 (1996-06-15), pages 226 - 238, XP002110995 *
CONLON J.M. ET AL.: "Somatostatin- and Urotensin II-related peptides: molecular diversity and evolutionary perspectives", REGULATORY PEPTIDES, vol. 69, no. 2, 26 March 1997 (1997-03-26), pages 95 - 103, XP002110991 *
COULOUARN Y. ET AL.: "Cloning of the cDNA encoding the Urotensin II precursor in frog and human reveals intense expression of the Urotensin II gene in motoneurons of the spinal cord", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 95, no. 26, 22 December 1998 (1998-12-22), pages 15803 - 15808, XP002110994 *
DATABASE EMBL NUCLEOTIDE SEQU 1 January 1900 (1900-01-01), XP002110997, Database accession no. AA535545 *
ITOH H. ET AL.: "Functional receptors for fish neuropeptide Urotensin II in major rat arteries", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 149, 1988, pages 61 - 66, XP002110996 *
MCMASTER D. ET AL.: "Characterization of the biologically and antigenically important regions of Urotensin II", PROCEEDINGS OF THE WESTERN PHARMACOLOGY SOCIETY, vol. 29, 1986, pages 205 - 208, XP002110992 *
PERKINS T.D.J. ET AL.: "Molecular modelling and design of analogues of the peptide hormone Urotensin II", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 18, no. 5, October 1990 (1990-10-01), pages 918 - 919, XP002110993 *

Also Published As

Publication number Publication date
WO1999035266A2 (fr) 1999-07-15
EP1045908A2 (fr) 2000-10-25
JP2002500045A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
EP1001023A3 (fr) Frizzled-4, un possible récepteur pour Wnt
WO1998031799A3 (fr) Polynucleotides et polypeptides codant des recepteurs
EP0939124A3 (fr) Séquences de la MBGP1
WO1999035266A3 (fr) Urotensine humaine ii
EP0911399A3 (fr) HTHBZ47, un clone apparenté à une kringle
WO2001004141A3 (fr) Seripancrine
EP0885959A3 (fr) Protéine Wnt-5b humaine
EP0943684A3 (fr) Polypeptides et polynucléotides ressemblant à frizzled
EP0879888A3 (fr) Polypeptides patched-2 et polynucléotides et leurs procédés de fabrication
EP0887416A3 (fr) Enzyme AFC1 humaine
WO1999011783A3 (fr) Polypeptides de boite t
EP0887415A3 (fr) RCE1 humain
WO2001083744A3 (fr) Nouvelle proteine echangeuse sodium-calcium
EP0911391A3 (fr) Clone HWHHJ20
EP0890646A3 (fr) HE2NW40 Sérine protéase
EP0882791A3 (fr) WNT-11 Polypeptides
EP0937777A3 (fr) Récepteurs de GABA et leurs utilisations
WO2001068816A8 (fr) Variant-3 du gene humain de l'histamine h3
EP0939123A3 (fr) SBPERR4, analogue du récepteur oestrogénique
EP0875570A3 (fr) Polypeptides neurodégénératives HHPDZ65
EP0969091A3 (fr) Protein associée à un gène récepteur de la leptine humaine
EP0949332A3 (fr) Polypeptides HSSCRG1
WO1999038885A3 (fr) Nouveaux composes
EP0974664A3 (fr) Polypeptides et polynucleotides humains ayant une homologie avec l'enzyme de conversion de l'angiotensine spécifique des testicules
WO2001085921A3 (fr) Nouvelle serine-threonine kinase-4

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1999902140

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 527650

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1999902140

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999902140

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载